Trial Profile

Phase Ia trial of ACH 3102 in healthy subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Apr 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odalasvir (Primary)
Indications Hepatitis C
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

23 Apr 2013 Status changed from recruiting to completed, based on information in Achillion Pharmaceuticals media releases.
27 Sep 2012 To date, 42 volunteers have received single dose ACH 3102 and 32 volunteers have received multiple-dose treatment, according to an Achillion Pharmaceuticals media release.
07 Aug 2012 Preliminary results published in an Achillion Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com